Arvinas
$11.37
25
+$0.15+1.34% Tuesday 20:00
Statistics
Day High
11.49
Day Low
10.8
52W High
14.51
52W Low
5.9
Volume
893,654
Avg. Volume
870,725
Mkt Cap
730.23M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
30AprExpected
Expected EPS
-0.919238
Actual EPS
N/A
Financials
-75.51%Profit Margin
Unprofitable526.8MRevenue
-397.8MNet Income
Analyst Ratings
$15.13Average Price Target
The highest estimate is 21.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy 75%
Hold 13%
Sell 13%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ARVN. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap187.56B
Gilead Sciences
GILD
Mkt Cap173.41B
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Novartis
NVS
Mkt Cap297.32B
Merck
MRK
Mkt Cap298.84B
Pfizer
PFE
Mkt Cap161.09B
Abbvie
ABBV
Mkt Cap369.39B
Roche
RHHBY
Mkt Cap321.08B
Lilly(Eli) &
LLY
Mkt Cap837.36B
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
About
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Show more...
CEO
Dr. Randy Teel Ph.D.
Employees
430
Country
US
ISIN
US04335A1051
Listings
0 Comments
Share your thoughts
FAQ
What is Arvinas stock price today?▼
The current price of ARVN is $11.37 USD — it has increased by +1.34% in the past 24 hours. Watch Arvinas stock price performance more closely on the chart.
What is Arvinas stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Arvinas stocks are traded under the ticker ARVN.
Is Arvinas stock price growing?▼
ARVN stock has risen by +0.35% compared to the previous week, the month change is a -16.4% fall, over the last year Arvinas has showed a +83.68% increase.
What is Arvinas market cap?▼
Today Arvinas has the market capitalization of 730.23M
When is the next Arvinas earnings date?▼
Arvinas is going to release the next earnings report on April 30, 2026.
What were Arvinas earnings last quarter?▼
ARVN earnings for the last quarter are -1.1 USD per share, whereas the estimation was -0.51 USD resulting in a -114.24% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Arvinas revenue for the last year?▼
Arvinas revenue for the last year amounts to 526.8M USD.
What is Arvinas net income for the last year?▼
ARVN net income for the last year is -397.8M USD.
How many employees does Arvinas have?▼
As of April 08, 2026, the company has 430 employees.
In which sector is Arvinas located?▼
Arvinas operates in the Health Care sector.
When did Arvinas complete a stock split?▼
Arvinas has not had any recent stock splits.
Where is Arvinas headquartered?▼
Arvinas is headquartered in New Haven, US.